The use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic renal disease
https://doi.org/10.14341/probl201258643-48
Abstract
The rapid increase in the number of patients with type 2 diabetes mellitus and renal pathology necessitates the revision of the presently adopted approaches to renal replacement therapy with a view of relieving the economic and financial burden imposed by the use of expensive therapeutic methods on the health budgets of the developed countries. The importance of achievement and maintenance of the target blood sugar levels for the prevention of the development and progression of renal lesions has been demonstrated in a series of large-scale clinical studies. Compensation of disorders of carbohydrate metabolism at the late stages of chronic renal disease in the patients presenting with diabetes mellitus encounters difficulties arising from the danger of hypoglycemia associated with the impairment of renal gluconeogenesis, cumulation of antiglycemic agents and their metabolites, decreased clinical significance of glycated hemoglobin levels under conditions of developing anemia and marked hyperglycemia. Discontentedness with the currently available means for the control of carbohydrate metabolism that fail to meet the up-to-date-requirements for the effectiveness and safety in a given clinical situation accounts for the ever increasing interest in the possibility of using innovative incretin-based medicines taking into account their pharmacological profile (they are known to change insulin secretion in response to variations in blood glucose levels, improve the function of beta-cells, have beneficial effect on the cardiovascular system, and control body weight).
About the Authors
M. Sh. Shamkhalova
Endocrinology Research Centre, Moscow
Russian Federation
Russian Federation
M. V. Shestakova
Endocrinology Research Centre, Moscow
Russian Federation
Russian Federation
References
1. Бикбов Б.Т., Томилина Н.А. Состояние заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998—2009 гг. Нефрология и диализ 2011; 3: 152—248.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression og long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977—986.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837—853.
4. Patel A., MacMahon S., Chalmers J. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560—2572.
5. Nathan D.M., Buse J.B., Davidson M.B., Ferranini E., Holman R.R., Sherwin R., Zimman B. American Diabetes Association,; European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193—203.
6. Kanjanabuch T., Ma L.J., Chen J. PPAR-gamma agonist protects podocytes from injury. Kidney Int 2007; 71: 1232—1239.
7. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular disease. N Engl J Med 2007; 356: 2457—2471.
8. Musso G., Gambino R., Cassader M., Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44: 375—393.
9. Neumiller J.J., Wood L., Cambell R.K. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010; 30: 463—484.
10. Mega C., Teixeira-De-Lemos E., Vala H., Fernandes R., Olievera J., Mascarenhas-Melo F., Teixeira F., Reia F. Diabetic nephropathy amelioration by low0dose sitagliptin in an animal model of type 2 diabetes (Zucker Diabetic Fatty Rat). Experimental Diabet Res 2011; 162092, doi: 1155/2011/162092.
11. Januvia (sitagliptin) prescribing information. Whitehouse Station. New York: Merck & Co Inc 2009.
12. Chan J.C.N., Scott R., Arjona Ferreira J.C., Sheng D., Gonzalez E., Davies M.J., Stein P.P., Kaufman K.D., Amatruda J.M., Williams-Herman D. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabet Obes Metabol 2008; 10: 545—555.
13. Odegaard D., Lane J., Haire C. Sitagliptin use in kidney transplant recipients: Effect on immunosuppressant levels. Diabetes 2008; 58: Suppl 1: A646.
14. Dowling T.C., Briglia A.E., Fink J.C. Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 2003; 73: 427—434.
15. Princeton N.J. Onglyza (saxagliptin) prescribing information. Bristol-Myers Squibb Company and Wilmington, DE. AstraZeneca Pharmaceuticals LP 2009.
16. Nowicki M., Rychlik I., Haller H., Warren M.L., Suchower L., Gause-Nilsson L. Saxagliptin improves glycaemic control and is well tolerated in type 2 diabetes and renal impairment. Diabet Obes Metabol 2011; 13: 523—532.
17. Graefe-Mody U., Friedrich C., Port A. et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabet Obes Metabol 2011; 13: 10: 939—946.
18. Cooper M., von Eynatten M., Emser A., Patel S., Woerle H.-J. Efficacy and Safety of Linagliptin in Patients with Type 2 Diabetes with or Without Renal Impairment: Results From a Global Phase 3 Program. American Diabetes Association, 71th Scientific Sessions. San Diego CA 2011; 1068.
19. Sloan L., Newman J., Sauce C., von Eynatten M., Patel S., Woerle H.-J. Safety and Efficacy of Linagliptin in Type 2 Diabetes Patients with Severe Renal Impairment. American Diabetes Association, 71th Scientific Sessions. San Diego CA 2011; 413.
20. He H., Tran P., Yin H. Absorption, metabolism and excretion of vildagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. Drug Metab Dis 2009; 536—544.
21. Ligueros-Saylan M., Ligueros-Saylan M., Foley J.E., Schweizer A., Couturier A., Kothny W. An assessment of adverse effect of vildagliptin versus comparators on the liver, pancreas, the immune system, the skin and patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabet Obes Metabol 2010; 495—509.
22. Ito M., Abe M., Okada K., Sasaki H., Maruyama N., Tsuchida M., Higuchi T., Kikuchi F., Soma M. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J 2011; 58: 11: 979—987.
23. Peacock T.P., Shihabi Z.K., Bleyer A.J., Dolbare E.L., Byers J.R., Knovich M.A., Calles-Escandon J., Russell G.B., Freedman B.I. Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Int 2008; 73: 1062—1068.
24. Lukashevich V., Schweizer A., Shao Q., Groop P.H., Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabet Obes Metab 2011; 13: 947—954.
25. Kothny W., Shao Q., Groop P.H., Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment/ Diabet Obes Metabol 2012; 14: 1032—1039.
26. Dejager S., Razac S., Foley J.E., Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007; 39: 218—223.
27. Schweizer A., Dejager S., Foley J.E., Kothny W. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag 2011; 7: 49—57.
28. European Medicines Agency. Galvus (vilagliptin) – European Public Assessment Report (EPAR). EMA /220510/2012. http://www.emea.europa.eu/Find medicine/Human medicines/European public assessment reports.
Review
For citations:
Shamkhalova M.Sh., Shestakova M.V. The use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic renal disease. Problems of Endocrinology. 2012;58(6):43-48. (In Russ.) https://doi.org/10.14341/probl201258643-48
Views:
376
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
